Consensus Statement from the International Radiosurgery Oncology Consortium for Kidney for Primary Renal Cell Carcinoma

References

• Torre LA , BrayF, SiegelRL, FerlayJ, Lortet-TieulentJ, JemalA. Global cancer statistics, 2012. CA Cancer J. Clin.65(2), 87–108 (2015).
   PubMed Web of Science ®Google Scholar
• Siegel R , NaishadhamD, JemalA. Cancer statistics, 2013. CA Cancer J. Clin.63(1), 11–30 (2013).
   PubMed Web of Science ®Google Scholar
• Malcolm JB , BagrodiaA, DerweeshIHet al. Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy. BJU Int.104(4), 476–481 (2009).
   PubMed Web of Science ®Google Scholar
• Kim SP , ThompsonRH, BoorjianSAet al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J. Urol.188(1), 51–57 (2012).
   PubMed Web of Science ®Google Scholar
• Demirjian S , LaneBR, DerweeshIH, TakagiT, FerganyA, CampbellSC. Chronic kidney disease due to surgical removal of nephrons: relative rates of progression and survival. J. Urol.192(4), 1057–1062 (2014).
   PubMed Web of Science ®Google Scholar
• Kunkle DA , UzzoRG. Cryoablation or radiofrequency ablation of the small renal mass. Cancer113(10), 2671–2680 (2008).
   PubMed Web of Science ®Google Scholar
• Zagoria RJ , HawkinsAD, ClarkPEet al. Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success. Am. J. Roentgenol.183(1), 201–207 (2004).
   PubMed Web of Science ®Google Scholar
• Lo SS , FakirisAJ, ChangELet al. Stereotactic body radiation therapy: a novel treatment modality. Nat. Rev. Clin. Oncol.7(1), 44–54 (2010).
   PubMed Web of Science ®Google Scholar
• Siva S , PhamD, GillS, CorcoranNM, ForoudiF. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int.110(11 Pt B), E737–E743 (2012).
   PubMedGoogle Scholar
• Staehler M , BaderM, SchlenkerBet al. Single fraction radiosurgery for the treatment of renal tumors. J. Urol.193(3), 771–775 (2015).
   PubMed Web of Science ®Google Scholar
• Pham D , ThompsonA, KronTet al. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity. Int. J. Radiat. Oncol. Biol. Phys.90(5), 1061–1068 (2014).
   PubMed Web of Science ®Google Scholar
• McBride SM , WagnerAA, KaplanID. A Phase 1 dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys.87(Suppl. 2), S84 (2013).
   Web of Science ®Google Scholar
• Ponsky L , LoSS, ZhangYet al. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma. Radiother. Oncol.117(1), 183–187 (2015).
   PubMed Web of Science ®Google Scholar
• Eisenhauer E , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Timmerman R , GalvinJ, GoreE, PassH, EdelmanM, KongF. RTOG 0618 A Phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with operable stage I/II non-small cell lung cancer. RTOG. Philadelphia, PA, USA (2007).
   Google Scholar
• Mickisch G , GarinA, Van PoppelH, De PrijckL, SylvesterR. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358(9286), 966–970 (2001).
   PubMed Web of Science ®Google Scholar
• Clinical trials database: NCT01099423. https://clinicaltrials.gov/ct2/show/NCT01099423.
   Google Scholar
• Clinical trials database: NCT00930033. https://clinicaltrials.gov/ct2/show/NCT00930033.
   Google Scholar
• Formenti SC , DemariaS. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl Cancer Inst.105(4), 256–265 (2013).
   PubMed Web of Science ®Google Scholar
• Siva S , MacmanusMP, MartinRF, MartinOA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett.356(1), 82–90 (2015).
   PubMed Web of Science ®Google Scholar
• Loh J , DavisID, MartinJM, SivaS. Extracranial oligometastatic renal cell carcinoma: current management and future directions. Future Oncol.10(5), 761–774 (2014).
   PubMed Web of Science ®Google Scholar
• Ortiz-Alvarado O , AndersonJK. The role of radiologic imaging and biopsy in renal tumor ablation. World J. Urol.28(5), 551–557 (2010).
   PubMed Web of Science ®Google Scholar
• Tsivian M , KimCY, CasoJR, RosenbergMD, NelsonRC, PolascikTJ. Contrast enhancement on computed tomography after renal cryoablation: an evidence of treatment failure?J. Endourol.26(4), 330–335 (2012).
   PubMed Web of Science ®Google Scholar
• Nielsen TK , ØstraatØ, AndersenG, H⊘yerS, GraumannO, BorreM. CT contrast enhancement following renal cryoablation – does it represent treatment failure?J. Endourol.29(12), 1353–1360 (2015).
   PubMed Web of Science ®Google Scholar
• Weight CJ , KaoukJH, HegartyNJet al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J. Urol.179(4), 1277–1283 (2008).
   PubMed Web of Science ®Google Scholar
• Ellis RJ , PatelRB, KunosCet al. Stereotactic radiosurgery for renal cancer: Phase I safety and toxicity. Int. J. Radiat. Oncol. Biol. Phys.84(3), S119 (2012).
   PubMedGoogle Scholar
• Crook J , PerryG, RobertsonS, EscheB. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology45(4), 624–632 (1995).
   PubMed Web of Science ®Google Scholar
• D’alimonte L , HelouJ, ShermanCet al. The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer. Brachytherapy14(3), 309–314 (2015).
   PubMed Web of Science ®Google Scholar
• Spaulding MB , FischerSG, WolfGT. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J. Clin. Oncol.12(8), 1592–1599 (1994).
   PubMed Web of Science ®Google Scholar
• Chan AW , AncukiewiczM, CarballoN, MontgomeryW, WangC. The role of postradiotherapy neck dissection in supraglottic carcinoma. Int. J. Radiat. Oncol. Biol. Phys.50(2), 367–375 (2001).
   PubMed Web of Science ®Google Scholar
• Chang JY , SenanS, PaulMAet al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol.16(6), 630–637 (2015).
   PubMed Web of Science ®Google Scholar